Phase II trial of regorafenib in patients with imatinib resistrant gastrointestinal stromal tumor
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms RESET for GIST
- 05 Jan 2017 Planned End Date changed from 18 Jan 2017 to 30 Sep 2018.
- 26 Jan 2015 Status changed from not yet recruiting to recruiting according to UMIN record.
- 16 Jan 2015 New trial record